Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907332 | 0.88 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL44676 | 0.85 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15058849 | 0.82 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL8485491 | 0.81 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL17167370 | 0.79 | KMT2A (0.56) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL13044481 | 0.79 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15119354 | 0.79 | KMT2A (0.60) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL4816547 | 0.78 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30662444 | 0.78 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL87486 | 0.78 | CA1 (0.50) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222117-A1 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | PURDUE RESEARCH FOUNDATION | 2025-07-10 | — | — | US | disclosed |
| EP-4463149-A2 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | Purdue Research Foundation (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118871104-A | Compounds, compositions, and methods of use comprising raltitrexed or 5-MTHF linked to a therapeutic agent | 普渡研究基金会 | 2024-10-29 | — | — | CN | disclosed |
| EP-4277709-A1 | DENTAL CARE PRODUCT | Dr. Kurt Wolff GmbH & Co. KG (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-20230331767-A1 | TARGETED STEROID COMPOUNDS | PURDUE RESEARCH FOUNDATION | 2023-10-19 | — | — | US | disclosed |
| WO-2023137403-A2 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2023-07-20 | — | — | WO | disclosed |
| CN-115397519-A | Antigenic polypeptides and methods of use thereof | 艾吉纳斯公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-4087580-A1 | TARGETED STEROID COMPOUNDS | Purdue Research Foundation (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-115003308-A | Targeted steroid compounds | 普渡研究基金会 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022152347-A1 | DENTAL CARE PRODUCT | DR. KURT WOLFF GMBH & CO. KG (DE) | 2022-07-21 | — | — | WO | disclosed |
| CN-114630837-A | Antigenic polypeptides and methods of use thereof | 艾吉纳斯公司 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331767-A1 | TARGETED STEROID COMPOUNDS | CYP11B2, FOLR2, CYP11B1 | KMT2A 4477/4885FABP5 394/4885FABP7 384/4885 |
| US-20250222117-A1 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | MTHFD1, MTHFD2, DHFR | KMT2A 2271/4885FABP5 870/4885FABP7 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.